Trial Profile
A Randomized, Blinded, Parallel Group, Multi-center Dose-finding Study, to Assess the Efficacy, Safety and Tolerability of Different Doses of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Tobramycin (Primary)
- Indications Bronchiectasis; Pseudomonal infections
- Focus Therapeutic Use
- Acronyms iBEST-1
- Sponsors Novartis; Novartis Pharmaceuticals
- 13 Sep 2023 Results determining changes in the antimicrobial resistome and airway microbiota followingtreatment with tobramycin inhalation powder (TIP) or placebo by extracting DNA from sputum collected at baseline and at day 29 from this study, presented at the 33rd Annual Congress of the European Respiratory Society
- 27 Aug 2020 Results determining the efficacy of a safe and well-tolerated dose and regimen of tobramycin inhalation powder (TIP) on Pseudomonas aeruginosa (Pa) sputum density in patients with bronchiectasis published in the European Respiratory Journal
- 20 May 2020 Primary endpoint (P. aeruginosa density in sputum) has been met, as per results presented at the 116th International Conference of the American Thoracic Society